Latest & greatest articles for Benign Prostatic Hyperplasia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Benign Prostatic Hyperplasia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on Benign Prostatic Hyperplasia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for Benign Prostatic Hyperplasia

121. Benign prostatic hyperplasia treatments

Benign prostatic hyperplasia treatments Benign prostatic hyperplasia treatments Benign prostatic hyperplasia treatments University HealthSystem Consortium Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation University HealthSystem Consortium. Benign prostatic hyperplasia treatments. Oak Brook, Illinois: University Healthsystem Consortium 1995: 148 Authors (...) ' objectives Reviews the therapeutic alternatives for treating BPH, forecasts trends in BPH therapy, and provides recommendations on the acquisition of these technologies in academic health centers and on clinical use of the therapies Project page URL Indexing Status Subject indexing assigned by CRD MeSH Prostatic Hyperplasia Language Published English Country of organisation United States Address for correspondence University HealthSystem Consortium, 2001 Spring Rd., Suite 700, Oak Brook, IL 60523 USA

1995 Health Technology Assessment (HTA) Database.

122. Benign prostatic hyperplasia

Benign prostatic hyperplasia Benign prostatic hyperplasia Benign prostatic hyperplasia NHS Centre for Reviews and Dissemination Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHS Centre for Reviews and Dissemination. Benign prostatic hyperplasia. University of York. Effective Health Care 2(2). 1995 Authors' objectives This report aims (...) to summarise the research evidence for the treatment of benign prostatic hyperplasia (BPH), or lower urinary tract symptoms in older men. Authors' conclusions Enlargement of the prostate affects about one third of men over 50 and can cause distressing urinary symptoms. The progress of benign prostatic hyperplasia (BPH) is unpredictable, but only a minority of men deteriorate rapidly and some will improve spontaneously. Many men willingly tolerate mild symptoms of BPH. Care should be taken not to overtreat

1995 Health Technology Assessment (HTA) Database.

123. Cost effectiveness and cost utility analyses of finasteride therapy for the treatment of benign prostatic hyperplasia - systematic review

Cost effectiveness and cost utility analyses of finasteride therapy for the treatment of benign prostatic hyperplasia - systematic review Cost effectiveness and cost utility analyses of finasteride therapy for the treatment of benign prostatic hyperplasia - systematic review Cost effectiveness and cost utility analyses of finasteride therapy for the treatment of benign prostatic hyperplasia - systematic review Baladi JF, Menon D Record Status This is a bibliographic record of a published health (...) technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Baladi JF, Menon D. Cost effectiveness and cost utility analyses of finasteride therapy for the treatment of benign prostatic hyperplasia - systematic review. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA). 1995 Authors' objectives To examine the cost-effectiveness of finasteride therapy in the treatment of benign prostatic hyperplasia

1995 Health Technology Assessment (HTA) Database.

124. Cost-effectiveness and cost-utility analyses of finasteride therapy for the treatment of benign prostatic hyperplasia

Cost-effectiveness and cost-utility analyses of finasteride therapy for the treatment of benign prostatic hyperplasia Cost-effectiveness and cost-utility analyses of finasteride therapy for the treatment of benign prostatic hyperplasia Cost-effectiveness and cost-utility analyses of finasteride therapy for the treatment of benign prostatic hyperplasia Canadian Coordinating Office for Health Technology Assessment Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Finasteride, 5 mg/day, for the treatment of benign prostatic hyperplasia (BPH) in elderly males. Type of intervention Treatment. Economic study type Cost-effectiveness analysis and cost-utility analysis. Study population Males, aged above 60 and experiencing symptoms

1995 NHS Economic Evaluation Database.

125. Economic modelling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia

Economic modelling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia Economic modelling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia Economic modelling to assess the costs of treatment with finasteride, terazosin, and transurethral (...) resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia Lowe F C, McDaniel R L, Chmiel J J, Hillman A L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Benign prostatic hyperplasia (BPH

1995 NHS Economic Evaluation Database.

126. [Therapy for benign prostatic hyperplasia]

[Therapy for benign prostatic hyperplasia] Terapeutica en la hiperplasia benigna [Therapy for benign prostatic hyperplasia] Terapeutica en la hiperplasia benigna [Therapy for benign prostatic hyperplasia] Albisu A, Vesga M, Pertusa C Citation Albisu A, Vesga M, Pertusa C. Terapeutica en la hiperplasia benigna. [Therapy for benign prostatic hyperplasia] Vitoria-Gasteiz: Basque Office for Health Technology Assessment (OSTEBA). D-94-02. 1994 Authors' objectives

To analyse the current available (...) therapies to treat Benign Prostatic Hyperplasia (BPH) and recommend those for which their efficacy is proved.

Authors' conclusions Conclusions: Transurethral ressection of the Prostate(TURP) is the selected treatment for the absolute intervention indication. In moderate prostatism cases it is possible to use reductase inhibitor and blocker treatment, which have shown objective impr ovement, with a minimum toxicity. Patients with a high surgical risk or those who wish to avoid the erection

1994 Health Technology Assessment (HTA) Database.

127. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. (Abstract)

The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. Benign prostatic hyperplasia is a progressive, androgen-dependent disease resulting in enlargement of the prostate gland and urinary obstruction. Preventing the conversion of testosterone to its tissue-active form, dihydrotestosterone, by inhibiting the enzyme 5 alpha-reductase could decrease the action of androgens in their target tissues; in the prostate the result might be a decrease in prostatic (...) in prostatic volume. The men given placebo had no changes in total urinary-symptom scores, an increase of 0.2 ml per second (8 percent) in the maximal urinary-flow rate, and a 3 percent decrease in prostatic volume. The frequency of adverse effects in the three groups was similar, except for a higher incidence of decreased libido, impotence, and ejaculatory disorders in the finasteride-treated groups.The treatment of benign prostatic hyperplasia with 5 mg of finasteride per day results in a significant

1992 NEJM Controlled trial quality: uncertain

128. Heat treatment of benign prostatic hyperplasia

Heat treatment of benign prostatic hyperplasia Heat treatment of benign prostatic hyperplasia Heat treatment of benign prostatic hyperplasia Duhamel G Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Duhamel G. Heat treatment of benign prostatic hyperplasia. Paris: L'Agence Nationale d'Accreditation d'Evaluation en Sante (ANAES) 1991: 18 (...) Authors' objectives To define recommendations for evaluation procedures concerning appliances using hyperthermia to treat benign prostatic hyperplasia at the request of the French Ministry of Social Affairs and the French National Committee for Medical Evaluation. Authors' conclusions Before being routinely used in clinical practice, all hyperthermia apparatuses must be submitted to approval procedures including technical tests demonstrating histologically proven tissue destruction, double-blind

1991 Health Technology Assessment (HTA) Database.